Kiniksa Pharmaceuticals International, Plc

  • Earnings Score
  • Moat Score
  • Market Cap $1.64B
  • PE -180
  • Debt $NaN
  • Cash $97.38M
  • EV $NaN
  • FCF $11.10M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$9.07M
EBIT-$16.72M
ROE-2%
ROA-3%
FCF$11.10M
Equity$437.01M
Growth Stability1
PE-180.48
PEG30.73
PB3.74
P/FCF147.38
P/S4.26
Price/Cash0.06
Net Margins-11%
Op. Margins-4%
Earnings CAGR-1%
Sales Growth YoY67%
Sales Growth QoQ3%
Sales CAGR2%
FCF CAGR0%
Equity CAGR7%
Earnings Stability-0.32
Earnings Growth YoY-8%
Earnings Growth QoQ225%
Earnings CAGR 5Y-6%
Sales CAGR 5Y15%
FCF CAGR 5Y2%
Equity CAGR 5Y17%
Earnings CAGR 3Y60%
Sales CAGR 3Y60%
FCF CAGR 3Y16%
Equity CAGR 3Y44%
Market Cap$1.64B
Revenue$384.10M
Assets$555.30M
Cash$97.38M
Shares Outstanding71.12M
Earnings Score6%
Moat Score8%
Working Capital215.35M
Current Ratio3.24
Shares Growth 3y1%
Equity Growth QoQ0%
Equity Growth YoY8%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.

SEC Filings

Direct access to Kiniksa Pharmaceuticals International, Plc (KNSA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Kiniksa Pharmaceuticals International, Plc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Kiniksa Pharmaceuticals International, Plc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -1%
Stability -32%
loading chart...

Kiniksa Pharmaceuticals International, Plc Discounted Cash Flow

Fully customizable DCF calculator online for Kiniksa Pharmaceuticals International, Plc.

= $113M
012345678910TV
fcf$11M$11M$11M$11M$11M$11M$11M$11M$11M$11M$11M$114M
DCF$10M$9.2M$8.4M$7.7M$7M$6.4M$5.8M$5.3M$4.8M$4.4M$44M
Value$113M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-----410%83%5%-11%
ROA--32%-64%-45%-67%2%-3%-3%
ROE--37%-72%-52%-85%46%3%-2%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--------
Debt over Equity--------
Growth Stability-------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-----471%23%15%
Earnings YoY growth-59%57%-0%-2%-216%-92%-6%
Equity YoY growth--411%-19%38%-41%114%11%17%
FCF YoY growth-72%87%-15%-7%-104%131%2%